Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Key facts
- Who runs it
- GC Biopharma Corp
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 1,806 people, planned
- Started
- Oct 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- vaccination of GC3114B
- Vaccination of Efluelda
- Record updated
- 20 October 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults aged 65 years or older at the time of IP vaccination
- Subjects who have voluntarily decided to participate in the study after receiving and understanding a detailed explanation of the study and provided written informed consent to comply with the precautions
Who cannot take part
- History of severe hypersensitivity reactions after previous influenza vaccination or to eggs or any component of the vaccine (see Section 6.1) (e.g., anaphylaxis)
- Record of an influenza vaccination within 24 weeks prior to IP vaccination
- Known or suspected history of impaired immune function, including congenital or acquired immunodeficiency disorders
- History or family history of Guillain-Barre syndrome
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older. The study will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.
Read full original descriptionShow less
After providing written informed consent, participants will undergo screening to determine whether they are eligible. Eligible participants will be randomly assigned to a study group and receive a single dose of the investigational product on Day 0.
Participants will record solicited adverse events in a subject diary from Day 0 through Day 7. The study site will contact participants by telephone on Day 7 to check on adverse events, concomitant medications, and diary completion. On Day 28, participants will visit the study site for safety follow-up and blood sampling. Participants will be monitored for serious adverse events for 6 months.
The 2 groups in the trial
- GC3114BTreatment being tested
inactivated, split influenza vaccine
Treatment: vaccination of GC3114B
- EflueldaExisting treatment, for comparison
Inactivated split influenza vaccine
Treatment: Vaccination of Efluelda
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
- Record updated
- 20 October 2026